Michael Goldberg, Surge Therapeutics founder and CEO
July 19, 2023 08:00 AM EDT
Financing

Im­munother­a­py dur­ing surgery? Surge Ther­a­peu­tics nabs $32M to ex­pand clin­i­cal plans af­ter first dos­ing

Amber Tong

Weeks ago, Surge Ther­a­peu­tics marked what CEO Michael Gold­berg hopes will go down in his­to­ry as a turn­ing point in can­cer care: the first time …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Jim Wilson's Gem­ma­Bio rais­es $34M to com­mer­cial­ize gene ther­a­pies for rare dis­eases

A service from the Financial Times